Washington Takes an Equity Stake: D-Wave’s $100 Million Grant Reshapes Quantum Funding Dynamics

D-Wave Quantum's $100M CHIPS Act grant with equity stake triggers 7% stock surge; CFO sells shares as revenue drops 81% but orders hit record $33.4M.

When the U.S. Department of Commerce unveiled more than $2 billion in quantum-computing grants under the CHIPS and Science Act on May 21, it attached an unusual string: the government would receive minority equity stakes in the companies it backs. D-Wave Quantum was the first to sign a letter of intent for $100 million, earmarked for developing superconducting annealing and gate-model systems. The arrangement signals a strategic departure from traditional grant-making, one that gives Washington direct exposure to the upside – and the risk – of the nascent quantum sector.

Markets wasted no time pricing in the news. D-Wave shares surged more than 7% on Thursday to close at €25.30 in European trading, briefly touching $30.22 on the New York Stock Exchange. Trading volume exploded to 54.2 million shares, 69% above the daily average. The stock has since eased slightly to €25.21, with a relative strength index of 49.4 suggesting neutral momentum. The market capitalisation now sits at roughly $10.9 billion, more than double the level seen earlier this year.

The rally unfolded against a backdrop of notable insider selling. Chief Financial Officer John Markovich sold 328,752 shares on May 22 at a weighted average price of $27.70, pocketing $9.1 million. The sale followed the exercise of stock options, a routine move, but it reduced his direct holdings by 19% to 1.44 million shares. The timing – in the middle of a volatile upswing fuelled by federal money – has raised eyebrows among retail investors.

Institutional investors, by contrast, have been adding exposure. HighTower Advisors increased its stake by 11.4% to 171,079 shares, and Federated Hermes also lifted its position. The diverging behaviour between the C-suite and large asset managers creates a picture of competing convictions.

Wall Street analysts remain broadly optimistic but split on valuation. Of 17 covering the stock, 14 rate it a buy, two a hold and one a sell, for a “Moderate Buy” consensus. The average 12-month price target stands at roughly $34. Targets range widely: Rosenblatt Securities sees $43, Canaccord Genuity recently trimmed its target to $41 from $43, while Mizuho holds at $29 with an “Outperform” rating.

D-Wave’s first-quarter results, reported on May 12, added nuance. Revenue dropped 81% year-on-year to $2.9 million, missing estimates as a large one-off system sale booked in the prior-year period did not recur. Yet new orders hit a record $33.4 million, a roughly 2,000% surge. A $20 million system sale to Florida Atlantic University and a $10 million quantum-computing-as-a-service contract with a Fortune 100 company anchor the pipeline. Cash and equivalents stood at $588.4 million, providing ample runway.

The next inflection point comes June 1, when D-Wave hosts its first investor day at the New York Stock Exchange under the banner “The D-Wave Difference”. Management is expected to detail the dual-platform strategy of annealing and gate-model systems, outline the technology roadmap, and explain how the $100 million federal commitment accelerates commercialisation. The event will test whether the government’s equity-for-grants model – and D-Wave’s record bookings – can translate the stock’s speculative momentum into operational substance.